CV 301

Drug Profile

CV 301

Alternative Names: CEA-MUC-1-TRICOM Vaccine; CEA-MUC-1/TRICOM; CV-301; CVAC-301; falimarev; inalimarev; PANVAC; PANVAC V/F; PANVAC-VF

Latest Information Update: 17 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Therion Biologics
  • Developer BN ImmunoTherapeutics; Bristol-Myers Squibb; National Cancer Institute (USA)
  • Class Cancer vaccines; Membrane glycoproteins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase II Bladder cancer; Colorectal cancer; Non-small cell lung cancer; Prostate cancer
  • Discontinued Breast cancer; Ovarian cancer; Pancreatic cancer

Most Recent Events

  • 12 Jul 2018 Phase-II trials in Colorectal cancer (Metastatic disease, Combination therapy) in USA (SC) (NCT03547999)
  • 20 Mar 2018 Phase-II trials in Prostate cancer (Combination therapy, Metastatic disease) in USA (SC) (NCT03315871)
  • 12 Mar 2018 Bavarian Nordic plans a phase II trial for Bladder cancer (Combination therapy with atezolizumab) in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top